IGC Pharma (NYSEMKT:IGC) Shares Down 8.9% – What’s Next?

Posted by Defense World Staff on Dec 6th, 2025

Shares of IGC Pharma, Inc. (NYSEMKT:IGC – Get Free Report) traded down 8.9% during trading on Friday . The stock traded as low as $0.3224 and last traded at $0.2970. 214,616 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 913,992 shares. The stock had previously closed at $0.3261.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of IGC Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $3.88.

View Our Latest Analysis on IGC

IGC Pharma Price Performance

The stock’s fifty day moving average price is $0.37 and its 200-day moving average price is $0.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.15 and a quick ratio of 0.98. The firm has a market cap of $27.58 million, a PE ratio of -2.70 and a beta of 0.24.

Institutional Investors Weigh In On IGC Pharma

An institutional investor recently raised its position in IGC Pharma stock. Virtu Financial LLC boosted its position in IGC Pharma, Inc. (NYSEMKT:IGC – Free Report) by 91.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,546 shares of the company’s stock after buying an additional 42,654 shares during the period. Virtu Financial LLC owned approximately 0.10% of IGC Pharma worth $37,000 as of its most recent SEC filing. Institutional investors and hedge funds own 3.87% of the company’s stock.

IGC Pharma Company Profile

(Get Free Report)

IGC Pharma, Inc, a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development.